QWM
ALNY icon

Quaker Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quaker Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302 Sell
1
-1
-50% -$302 ﹤0.01% 839
2026
Q1 		$662 Hold
2
– – ﹤0.01% 637
2025
Q4 		$796 Hold
2
– – ﹤0.01% 588
2025
Q3 		$912 Buy
2
+1
+100% +$407 ﹤0.01% 485
2025
Q2 		$327 Buy
+1
New +$277 ﹤0.01% 700

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quaker Wealth Management's ALNY Position: Q2 2026 in Review

Quaker Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q2 2026, selling an estimated $302 and leaving 1 share worth $302. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Quaker Wealth Management first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $912 in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Quaker Wealth Management held 1 share of Alnylam Pharmaceuticals worth $302 as of Q2 2026.
  • Quaker Wealth Management sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #839 holding.
  • Quaker Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quaker Wealth Management's Alnylam Pharmaceuticals position peaked at $912 in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.